Efficacy and Safety of Apixaban and Enoxaparin for Thromboprophylaxis after Total Hip Arthroplasty

To explore its safety and efficacy for thromboprophylaxis of apixaban and enoxaparin after total hip arthroplasty (THA) patients. The study was designed as a prospective observational study, and all 70 patients who met the inclusion and exclusion criteria and underwent elective total hip (THA) arthroplasty between 1 January 2021 and 30 June 2022 were randomly assigned to Apixaban (Twice daily Dose 2.5 mg orally) or enoxaparin (Dose 60 mg every 24 hours subcutaneously), 35 patients were treated with apixaban and 35 patients were treated with enoxaparin. Apixaban treatment was started 12 to 24 hours after surgical wound closure and enoxaparin treatment was started 12 hours before surgery. A venogram was repeated at 42 days with postoperative prophylaxis. SPSS 28.0 was used to analyze the data, P < 0.05 was significant difference.The experiment compared the prices of them. The 70 patients included in the study were lost to follow-up due to possible reasons, and only 51 patients completed the trial in the end, including 26 patients apixaban and 25 patients enoxaparin. In studies apixaban at Dose 2.5 mg had similar to 60 mg daily and had similar bleeding characteristics. And there were no differences at 90-day. Price comparison prompts thatEnoxaparin cost more than apixaban throughout the trial period. symptomatic was lower in the apixaban group. Oral administration of apixaban showed better safety, similar efficacy, lower Price and better compliance hip arthroplasty in patients.